Hansa Medical AB (STO:HMED) announced on Thursday that under the authorisation by the annual general meeting held on 29 May 2018, the company's board of directors of has resolved to issue and immediately thereafter repurchase 391,503 class C shares.
These shares are issued and repurchased in accordance with the incentive programme LTIP 2018, which was adopted by the annual general meeting held on 29 May 2018.
Reportedly, Carnegie Investment Bank AB will subscribe for the entire issue of new class C shares at a subscription price of SEK1 per share, corresponding to the quota value of the shares. The entire issue of class C shares will thereafter, in accordance with the board of directors' resolution, be repurchased by Hansa Medical for the same price.
These class C shares will be converted into ordinary shares prior to delivery to qualifying participants of LTIP 2018.
According to the company, the purpose of the repurchase is to ensure delivery of shares and to secure possible social charges arising as a result of LTIP 2018. These class C shares do not entitle to dividends and each share entitles to 1/10 voting right.
Hansa Medical has previously issued 330,261 class C shares.
Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases.
(EUR1.00=SEK10.59)
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca